Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Home/Newsroom/

Arrowhead Pharmaceuticals to Host...

PASADENA, Calif.–(BUSINESS WIRE)–Sep. 24, 2018–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it
will host a Research & Development (R&D) Day to discuss its emerging
pipeline of RNAi therapeutics that leverage its proprietary Targeted
RNAi Molecule (TRIMTM) platform on October 16, 2018 in New
York City.

The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU
Langone Medical Center) who will discuss the current treatment landscape
and unmet medical need for patients with dyslipidemia and
hypertriglyceridemia.

Arrowhead’s management team will provide an overview of the company’s
pipeline of RNAi-based therapeutics. Discussion topics will include:

  • ARO-APOC3 for patients with hypertriglyceridemia. A CTA filing is
    planned by the end of 2018.
  • ARO-ANG3 for patients with dyslipidemia. A CTA filing is planned by
    the end of 2018.
  • ARO-ENaC for patients with cystic fibrosis. A CTA filing is planned in
    2019.
  • ARO-HIF2 for patients with renal cell carcinoma. A CTA filing is
    planned in 2019.

This event is intended for institutional investors, sell-side analysts,
investment bankers, and business development professionals only. Please
RSVP in advance if you plan to attend, as space is limited. To reserve a
seat, please click
here to register.

A live and archived webcast of the event, with slides, may be accessed
on the Events
and Presentations page under the Investors section of the Arrowhead
website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform
Act:

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com